Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.65 |
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | PNP | P00491 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 6/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506297 | 0.95 | HINT1 (0.67) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3514472 | 0.85 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17355882 | 0.85 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.85 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Guanosine SCHEMBL27648264 | 0.85 | HPGD (0.74) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17367941 | 0.85 | HINT1 (0.61) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2057327 | 0.85 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.84 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 0.84 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7111080 | 0.84 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519110-B2 | mRNA cap analogs | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2297175-B1 | MRNA CAP ANALOGS | UNIV WARSZAWSKI (PL) | 2013-08-07 | — | — | EP | disclosed |
| US-20110092574-A1 | mRNA Cap Analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | disclosed |
| EP-2297175-A2 | MRNA CAP ANALOGS | Uniwersytet Warszawski (PL) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009149253-A2 | MRNA CAP ANALOGS | UNIWERSYTET WARSZAWSKI (PL) | 2009-12-10 | — | — | WO | disclosed |
| US-5434143-A | ANTILIPEMIC AGENTS, ANTITUMOR AGENTS AND ANTIINFLAMMATORY AGENTS | BORON BIOLOGICALS, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0651758-A4 | PHOSPHITE-BORANE COMPOUNDS, AND METHOD OF MAKING THE SAME. | — | 1995-06-14 | — | — | EP | disclosed |
| EP-0651758-A1 | PHOSPHITE-BORANE COMPOUNDS, AND METHOD OF MAKING THE SAME | BORON BIOLOGICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994001444-A1 | PHOSPHITE-BORANE COMPOUNDS, AND METHOD OF MAKING THE SAME | BORON BIOLOGICALS, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-5260427-A | Nucleosidylphosphite-borane compounds and method of making the same | BORON BIOLGICALS, INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092574-A1 | mRNA Cap Analogs | RNMT, RNGTT, NSUN2 | HINT1 1367/4885NT5E 2213/4885GSK3A 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.